Ethanolamine Oleate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5%
Reference Brands: Generic formulations marketed under different names
Category:
Gastrointestinal Drugs
Ethanolamine Oleate is available in Injection
and strengths such as 5%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ethanolamine Oleate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ethanolamine Oleate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ethanolamine oleate is a sclerosing and antivaricose agent used primarily in endoscopic sclerotherapy for the management of esophageal varices. It is administered by direct injection into or around variceal veins, where it produces localized endothelial damage leading to inflammation, thrombosis, and eventual sclerosis or closure of the abnormal vein. This mechanism helps control active bleeding and reduces the risk of rebleeding in patients with esophageal varices that have recently hemorrhaged.
Ethanolamine oleate is specifically indicated for patients with a history of bleeding esophageal varices and is not recommended for use in patients whose varices have not bled. Clinical evidence has not demonstrated a preventive benefit in non-bleeding varices, and its use in such cases does not reduce the likelihood of future hemorrhage. Importantly, ethanolamine oleate does not address the underlying cause of esophageal varices, namely portal hypertension. As a result, recanalization of treated veins and the development of collateral circulation may occur over time. For this reason, repeated sclerotherapy sessions may be necessary to maintain therapeutic control and manage recurrent variceal bleeding in affected patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing